Effect of dobutamine combined with meropenem on serum BNP, IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP in children with congenital heart disease and pneumonia

摘要

Objective: To study the effect of dobutamine combined with meropenem on serum BNP,IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP in children with congenital heart disease andpneumonia. Methods: A total of 70 children with congenital heart disease and pneumoniain our hospital from June 2014 to Octomber 2016 were enrolled in this study. The subjectswere divided into the control group (n=35) and the treatment group (n=35) randomly. Thecontrol group was treated with dobutamine, the treatment group were treated with dobutaminecombined with meropenem. The two groups were treated for 10 days. The serum BNP,IGF-1, IGFBP-3, TNF-a, IL-6 and hs-CRP levels of the two groups before and after treatmentwere compared. Results: There were no significantly differences of the serum BNP, IGF-1,IGFBP-3, TNF-a, IL-6 and hs-CRP levels of the two groups before treatment. The serum BNP,TNF-a, IL-6 and hs-CRP levels of the two groups after treatment were significantly lower thanbefore treatment, the serum IGF-1 and IGFBP-3 levels of the two groups after treatment weresignificantly higher than before treatment, and that of the treatment group were significantlybetter than the control group. Conclusion: Dobutamine combined with meropenem cansignificantly reduce the serum BNP, TNF-a, IL-6 and hs-CRP levels, improve serum IGF-1 andIGFBP-3 levels of children with congenital heart disease and pneumonia, and it was worthyclinical application.